Synthesis of new anthranilic acid dimer derivatives and their evaluation on CCK receptors

Farmaco

Volumn 55, Issue 5, 2000, Pages 369-375

  Varnavas, Antonio ^a   Lassiani, Lucia ^a   Valenta, Valentina ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Anthranilic acid dimer; CCK receptor ligands

Indexed keywords

ANTHRANILIC ACID DERIVATIVE; ASPERLICIN; CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; PROPIONIC ACID DERIVATIVE; TRYPTOPHAN;

ANIMAL EXPERIMENT; ARTICLE; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; GUINEA PIG; LIGAND BINDING; MALE; NONHUMAN; RAT; RECEPTOR AFFINITY;

ANIMALS; ANTHRANILIC ACIDS; DIMERIZATION; DRUG EVALUATION; GUINEA PIGS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MOLECULAR STRUCTURE; RATS; RATS, WISTAR; RECEPTORS, CHOLECYSTOKININ;

EID: 0033863317     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(00)00053-7     Document Type: Article

References (26)

1. Williams J.A. Cholecystokinin: a hormone and a neurotransmitter. Biomed. Res. 3:1982;107-115.
2. Reeve J.R., Eysselein V., Walsh J.H., Ben Avram C.M., Shively J.E. New molecular forms of cholecystokinin. Microsequence analysis of forms previously characterized by chromatographic methods. J. Biol. Chem. 261:1986;16392-16397.
3. Larsson L.I., Rehfeld J.F. Localization and molecular heterogeneity of cholecystokinin in the central and peripheral nervous systems. Brain Res. 165:1979;201-218.
4. Jensen R.T., Wank S.A., Rowley W.H., Sato S., Gardner J.D. Interaction of CCK with pancreatic acinar cells. Trends Pharmacol. Sci. 10:1989;418-423.
5. Liddle R.A., Gertz B.J., Kanayama S., Beccaria L., Coker L.D., Turnbull T.A., Morita E.T. Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK. J. Clin. Invest. 84:1989;1220-1225.
6. Meyer B.M., Werth B.A., Beglinger C., Hildebrand P., Jansen J.B., Zach D., Rovati L.C., Stalder G.A. Role of cholecystokinin in regulation of gastrointestinal motor functions. Lancet. 2:1989;12-15.
7. Brawman Mintzer O., Lydiard R.B., Bradwejn J., Villarreal G., Knapp R., Emmanuel N., Ware M.R., He Q., Ballenger J.C. Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder. Am. J. Psychiatry. 154:1997;700-702.
8. van-Megen H.J., den-Boer J.A., Westenberg H.G. On the significance of cholecystokinin receptors in panic disorder. Prog. Neuropsycho-pharmacol. Biol. Psychiatry. 18:1994;1235-1246.
9. Lofberg C., Agren H., Harro J., Oreland L. Cholecystokinin in CSF from depressed patients: possible relations to severity of depression and suicidal behaviour. Eur. Neuropsycopharmacol. 8:1998;153-157.
10. Benedetti F., Amanzio M., Casadio C., Oliaro A., Maggi G. Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide. Pain. 71:1997;135-140.
11. Pi-Sunyer F.X., Kissileff H.R., Thornton J., Smith G.P. C-terminal octapeptide of cholecystokinin decrease food intake. Physiol. Behav. 29:1982;627-630.
12. Dourish C.T., Hill D.R. Classification and function of CCK receptors. Trends Pharmacol. Sci. 8:1987;207-209.
13. de Tullio P., Delarge J., Pirotte B. Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists). Curr. Med. Chem. 6:1999;433-455.
14. Chang R.S., Lotti V.J., Monaghan R.L., Birnbaum J., Stapley E.O., Goetz M.A., Albers-Schonberg G., Patchett A.A., Liesch J.M., Hensens O.D., Springer J.P. A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus. Science. 230:1985;177-179.
15. Evans B.E., Bock M.G., Rittle K.E., Di Pardo R.M., Whitter W.L., Veber D.F., Anderson P.S., Freidinger R.M. Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin. Proc. Natl Acad. Sci. USA. 83:1986;4918-4922.
16. Bock M.G., Di Pardo R.M., Evans B.E., Rittle K.E., Whitter W.L., Veber D.F., Anderson P.S., Freidinger R.M. Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260. J. Med. Chem. 32:1989;13-16.
17. Yu M.J., Thrasher K.J., McCowan J.R., Mason N.R., Mendelsohn L.G. Quinazolinone cholecystokinin-B receptor ligands. J. Med. Chem. 34:1991;1505-1508.
18. Varnavas A., Lassiani L., Luxich E., Zacchigna M. Anthranoyl-anthranilic acid: a template for the development of a new class of cholecystokinin receptor ligands. Pharmazie. 51:1996;697-700.
19. Eden J.M., Higginbottom M., Hill D.R., Horwell D.C., Hunter J.C., Martin K., Pritchard M.C., Rahman S.S., Richardson R.S., Roberts E. Rationally designed dipeptoid analogues of cholecystokinin (CCK): N-terminal structure-affinity relationships of alpha-methyl tryptophan derivatives. Eur. J. Med. Chem. 28:1993;37-45.
20. Boden P.R., Eden J.M., Higginbottom M., Hill D.R., Horwell D.C., Hunter J.C., Martin K., Pritchard M.C., Richardson R.S., Roberts E. Rationally designed dipeptoid analogues of cholecystokinin (CCK): C-terminal structure-activity relationships of alpha-methyl tryptophan derivatives. Eur. J. Med. Chem. 28:1993;47-61.
21. Varnavas A., Lassiani L., Luxich E., Valenta V. C-terminal anthranoyl-anthranilic acid derivatives and their evaluation on CCK receptors. Farmaco. 55:2000;293-302.
22. 3H]-(±)-L-364,718: a new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors. Mol. Pharmacol. 30:1986;212-217.
23. 3H]-L-365,260: a new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand. Mol. Pharmacol. 35:1989;803-808.
24. Bock M.G., Di Pardo R.M., Rittle K.E., Evans B.E., Freidinger R.M., Veber D.F., Chang R.S.L., Chen T.B., Keegan M.E., Lotti V.J. Cholecystokinin antagonists. Synthesis of asperlicin analogues with improved potency and water solubility. J. Med. Chem. 29:1986;1941-1945.
25. Kermack W.O., Perkin W.H., Robinson R. Harmin and harmaline. Part V. The synthesis of norharman. J. Chem. Soc. 119:1921;1602-1642.
26. Bock M.G., Di Pardo R.M., Evans B.E., Rittle K.E., Veber D.F., Freidinger R.M., Hirshfield J., Springer J.P. Synthesis and resolution of 3-amino-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones. J. Org. Chem. 52:1987;3232-3239.